Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The brokerage presently has a $9.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 11.56% from the stock’s current price.

According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “

Other analysts also recently issued reports about the stock. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Sunday, July 16th. Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Finally, Leerink Swann reissued an “outperform” rating and set a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $12.38.

Shares of Adaptimmune Therapeutics PLC (ADAP) traded up 0.46% on Wednesday, hitting $8.74. 224,342 shares of the stock traded hands. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $9.29.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. The firm had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.43 million. On average, equities analysts expect that Adaptimmune Therapeutics PLC will post ($0.99) earnings per share for the current year.

WARNING: This story was published by Marea Informative and is owned by of Marea Informative. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at http://www.mareainformativa.com/adaptimmune-therapeutics-plc-adap-upgraded-at-zacks-investment-research/116103/.

Institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James Financial Services Advisors Inc. purchased a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $120,000. KCG Holdings Inc. purchased a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $133,000. Monashee Investment Management LLC purchased a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $138,000. OxFORD Asset Management LLP purchased a new position in Adaptimmune Therapeutics PLC during the second quarter valued at $156,000. Finally, Paloma Partners Management Co purchased a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $165,000. 68.01% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.